Open AccessCARDIOVASCULAR COMPLICATIONS OF ANTICANCER THERAPY: CLINICAL FEATURES, DIAGNOSIS, TREATMENT, PREVENTION (PART II)
Author(s) -
Н. Т. Ватутин,
E. V. Sklyannaya,
М. А. Эль-Хатиб,
Г. Г. Тарадин
Publication year - 2018
Publication title -
rossijskij onkologičeskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2412-9119
pISSN - 1028-9984
DOI - 10.18821/1028-9984-2018-23-1-43-49
Subject(s) - cardiotoxicity , medicine , chemotherapy , heart failure , anthracycline , pharmacology , etiology , cancer , breast cancer
The given review is devoted to the problem of the cardiotoxicity of chemotherapeutic agents. Many of chemotherapeutic agents can cause cardiovascular complications such as left ventricular dysfunction and heart failure development, myocardial ischemia, arterial hypertension, thromboembolism, QT prolongation and arrhythmias. The toxic influence of the most often used chemotherapeutic agents on heart (such as antimetabolites, alkylating agents, platinum compounds, taxanes, vinca alkaloids, monoclonal antibodies, anthracycline antibiotics, topoisomerase and protein kinase inhibitors, immunomodulatory agents and cytokines) has been described. The results of recent studies on etiology, pathogenesis and clinical features of chemotherapy-induced cardiotoxicity were present in the first part of review. The clinical features, diagnosis, treatment and prevention of the cardiotoxicity of chemotherapeutic agents, are described in the second part of the review